IVERMECTIN, HYDROXYCHLOROQUINE, AND INHALED APROTININ AGAINST COVID-19

A pharmaceutical research company based in Turku, Finland, has developed a new medication for the treatment of Covid-19. This is a nasal spray containing aprotinin, hydroxychloroquine, and ivermectin as active components, with the latter two already known to be effective for the prevention and early-stage treatment of Covid-19.

The coronavirus medication was developed by Therapeutica Borealis Oy, a Finnish pharmaceutical company, and received approval from the United States Patent and Trademark Office on May 18, 2021. The inventors of the drug are Kalervo Väänänen and Lauri Kangas, professors at the University of Turku, and Matti Rihko, a psychologist and partner at Therapeutica Borealis Oy.

The patent, filed on May 11, 2020, protects an intranasal medication (nasal spray) for inhibiting Covid-19, a disease caused by the SARS-CoV-2 virus (coronavirus). The medication combines aprotinin, hydroxychloroquine phosphate or hydroxychloroquine sulfate, ivermectin, in addition to other combinations using bafilomycin and ammonium.

If approved by the FDA (the American equivalent of Brazil's Anvisa), the medication can be commercialized in the United States for the prevention and weakening of the virus's ability to enter the human body, thereby reducing the possibility of acquiring the disease.

The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use.

This content is part of Clínica Revitalize's commitment to translating science into accessible clinical practice — without losing rigor or depth.